Circulating MiR-126 as a potential biomarker in Egyptian colorectal cancer patients: A case-control study.

BACKGROUND

Globally, colorectal cancer (CRC) is among the most prevalent malignant tumors. It is characterized by unlimited proliferation, invasion, and metastasis. MicroRNA-126 (miR-126) has been shown in many studies to play a significant role in CRC, but data regarding its role in CRC Egyptian patients are limited.

OBJECTIVES

This case-control study aimed to investigate the miR-126 as a potential marker in CRC Egyptian patients and to correlate its expression levels with CRC tumor, node, metastasis (TNM) stage, distant metastasis, and tumor size.

METHODS

The study included 50 adult Egyptian participants (30 patients with CRC, 10 patients with colorectal adenoma as a pathological control, and 10 healthy controls). MiR-126 expression levels were detected using Real-Time Quantitative PCR (qPCR) along with the endogenous reference gene hsa-miR-103a in all participants.

RESULTS

MiR-126 expression was significantly decreased in CRC patients than both control groups. It was associated with advanced TNM stage (= 0.001) and distant metastasis (= 0.002). However, it was not correlated with tumor size (= 0.980), carcinoembryonic antigen (CEA) (= 0.397), and cancer antigen 19-9 (CA19-9) (= 0.236). The best cut-off point of miR-126 to discriminate CRC from both controls was 0.7 and to discriminate metastatic CRC from non-metastatic CRC was 0.3.

CONCLUSIONS

Our results suggest that miR-126 could be used as an early marker for CRC detection among Egyptian patients and a good prognostic indicator associated with metastasis.